SCHEMBL2762199

SCHEMBL2762199

CCCCCCOc1ccc2c(c1)C(=O)OC(C)(C)O2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ PTPN1 P18031 1/20 0.44
▸ PTPN11 Q06124 2/20 0.44
▸ THRA P10827 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ TSHR P16473 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MMP2 P08253 1/20 0.42
▸ MMP3 P08254 1/20 0.42
▸ MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494139 0.77 MAOB (0.57) MEN1ALDH1A1KMT2AHPGDNPSR1
SCHEMBL31217566 0.77 PPIB (0.54) MEN1ALDH1A1KMT2AKDM4EHPGD
SCHEMBL25961101 0.75 TDP1 (0.43) ALDH1A1HPGDNPSR1L3MBTL1TDP1
SCHEMBL3029678 0.75 MAOB (0.43) L3MBTL1TDP1
SCHEMBL6935038 0.75 KDM4E (0.69) MEN1ALDH1A1KMT2AKDM4EHPGD
SCHEMBL7271528 0.75 PTPN11 (0.53) MEN1ALDH1A1KMT2AL3MBTL1PTPN1
SCHEMBL27710083 0.75 PTPN11 (0.53) MEN1ALDH1A1KMT2AL3MBTL1PTPN1
SCHEMBL11834242 0.75 PTPN11 (0.53) MEN1ALDH1A1KMT2AL3MBTL1PTPN1
SCHEMBL13709098 0.74 CYP3A4 (0.47) MEN1ALDH1A1KMT2AHPGDNPSR1
SCHEMBL1815941 0.73 CYP1A2 (0.46) MEN1ALDH1A1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 — — US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 — — US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 MEN1 3877/4885ALDH1A1 202/4885KMT2A 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback